Press Release

Morrison & Foerster Publishes New Issue of MoFo Tech, the Award-Winning Magazine of Law, Technology and Business

28 May 2013

SAN FRANCISCO (May 28, 2013) – Morrison & Foerster recently published the latest issue of MoFo Tech, the firm's award-winning magazine focusing on news, trend-spotting and analysis for science and technology companies.

Here is a link to the spring/summer issue.

The current issue's cover story offers an in-depth look at how President Obama's second term is likely to play out for the technology industry – from the appointment of the country's first chief technology officer to the president's call to reverse government spending cuts on research and development, as well as legislative and regulatory efforts to prevent a destabilizing cyberattack on the nation.

Since its launch in 2009, MoFo Tech is one of the only magazines to focus on the intersection of law and technology. Written by prominent business and tech journalists, MoFo Tech has won the Custom Publishing Council's Pearl Award four years running and was named "Best New Magazine" in its class. Its readership has grown each year and now surpasses 20,000, which primarily includes C-level executives and general counsel at many of the country's top tech and life sciences companies. MoFo Tech is also distributed at major airport executive lounges.

Last year, MoFo added an online companion with the launch of the MoFo Tech Blog (www.mofotechblog.com), offering each issue digitally, with updates on stories and additional content. MoFo Tech can also be followed on Twitter, @MoFoTech, and on the firm's mobile app, MoFo2Go, available on iPhone and iPad through Apple's App Store.

The blog also arrives on the heels of a new survey jointly conducted by Morrison & Foerster and leading technology market intelligence firm 451 Research, which explored M&A trends in the tech sector. The M&A Leaders Survey is designed to take the pulse of tech industry insiders on the dealmaking market, and represents the views of nearly 200 investment bankers, venture capitalists, financial advisers and senior executives. Read the full report here.

"Our technology practice has long been one of the cornerstones of the firm, and it's from this strong foundation that MoFo Tech was created," said Tessa Schwartz co-chair of the firm's Technology Transactions Group and one of the partners in charge of the magazine. "We've been extremely pleased at the penetration of MoFo Tech among so many key decision makers in the industry – especially as we continue to make our content available on digital platforms."

"There is really no other publication like it," said Morrison & Foerster intellectual property litigator Michael Jacobs, a partner who also directs the magazine's content. "Each issue gets richer in terms of news, analysis, trend-watching and thought leadership."

Among some of the other topics covered in the new issue of MoFo Tech:

  • The recent rise of 3-D printing has opened up the ability to digitally build intricate objects such as heavy machinery, aircraft components and replacement parts for consumer products, launching a new chapter in the file-sharing debate, and a potentially new theater in patent and copyright infringement.
     
  • Morrison & Foerster's proprietary BioMeter deal index reports that the average development costs for new therapeutics and other biotech products rose to $1.3 billion in 2011, up from $54 million in 1979 and $231 million in 1991. Also trending up, according to BioMeter: The percentage of biotech deals for already-approved assets – until 2012, when the trend reversed itself, perhaps signaling a fresh phase in the biotech deal market.
     
  • LEED (Leadership in Energy and Environmental Design) is spreading from building specifications to plans for entire corporate parks, marking a new holistic approach to fighting greenhouse gases that encompasses elements such as landscaping and commuter transportation.
     
  • Two American exchange students who met in China went on to form a successful capital management firm that pioneered biopharma royalty bonds, by which young companies with a new product receive royalty payments from established firms that agree to manufacture and market the products. When the term of the bond is up, ownership and royalties revert to the original company. This company, Capital Royalty, has since branched out into other innovative ways of investing venture capital in healthcare startups.
Close

Feedback

Disclaimer

Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.